Mesoblast Ltd ADR (MESO)

$19.40 +0.21 (1.09%)
Market Cap 2.46B
Revenue (ttm) 17.20M
Net Income (ttm) -102.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -593.84%
Debt to Equity Ratio 0.20
Volume 36,200
Avg Vol 203,692
Day's Range N/A - N/A
Shares Out 128.30M
Stochastic %K 79%
Beta 2.03
Analysts Strong Sell
Price Target $35.00

Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic ref...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
Address:
55 Collins Street, Level 38, Melbourne, Australia
Doozio
Doozio Dec. 19 at 7:25 PM
$MESO much moar 🐒🍌🧠⏰♾️
0 · Reply
Portman62
Portman62 Dec. 16 at 3:02 PM
$MESO technicals show bullish for the next 9 months, I still see $22.00 before the end of the year … steady as she goes.
1 · Reply
Mani86
Mani86 Dec. 15 at 2:31 AM
$MESO https://www.marketindex.com.au/asx/msb/announcements/study-at-ash-concludes-remestemcell-superiority-in-sragvhd-3A683770
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 12 at 3:17 PM
$MESO Current Stock Price: $18.22 Contracts to trade: $20 MESO Dec 19 2025 Call Entry: $0.20 Exit: $0.27 ROI: 37% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Mani86
Mani86 Dec. 4 at 5:03 PM
$MESO After looking at the short squeeze in Capricor , shorters in mesoblast should get very worried cause one fine day the squeeze will come and they would have no choice but to buy back at significantly higher price☝️
0 · Reply
Portman62
Portman62 Dec. 3 at 3:09 PM
$MESO Let’s go MESO, I see nothing keeping you down, solid stock with a great history and future. 👏🏽👏🏽👏🏽
0 · Reply
zipperson
zipperson Nov. 26 at 6:07 PM
$MESO
0 · Reply
zipperson
zipperson Nov. 25 at 8:36 PM
$MESO
0 · Reply
zipperson
zipperson Nov. 25 at 4:50 PM
$MESO This is huge beating estimate by 50%.
0 · Reply
Portman62
Portman62 Nov. 25 at 2:34 PM
$MESO … and away we go, as it should.
0 · Reply
Latest News on MESO
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

Dec 11, 2025, 6:22 PM EST - 13 days ago

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

Mesoblast Participation at Piper Sandler Conference

Dec 3, 2025, 6:10 PM EST - 21 days ago

Mesoblast Participation at Piper Sandler Conference

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

Nov 24, 2025, 6:39 PM EST - 4 weeks ago

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

Nov 20, 2025, 6:32 PM EST - 4 weeks ago

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

James M. O'Brien Appointed Chief Financial Officer at Mesoblast

Nov 17, 2025, 1:52 AM EST - 5 weeks ago

James M. O'Brien Appointed Chief Financial Officer at Mesoblast

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

Nov 4, 2025, 6:40 PM EST - 7 weeks ago

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

Oct 19, 2025, 7:48 PM EDT - 2 months ago

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

Oct 6, 2025, 7:24 PM EDT - 2 months ago

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Oct 6, 2025, 8:09 AM EDT - 2 months ago

Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session

IONQ QBTS QUBT RGTI

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

Oct 2, 2025, 9:04 PM EDT - 2 months ago

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

Sep 26, 2025, 1:49 AM EDT - 3 months ago

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

Sep 14, 2025, 9:18 PM EDT - 3 months ago

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Sep 3, 2025, 9:47 PM EDT - 4 months ago

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript

Aug 29, 2025, 12:27 PM EDT - 4 months ago

Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Aug 28, 2025, 8:24 PM EDT - 4 months ago

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Successful Commercial Launch of Ryoncil®

Jul 17, 2025, 8:38 PM EDT - 5 months ago

Successful Commercial Launch of Ryoncil®

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

Jul 1, 2025, 8:46 AM EDT - 6 months ago

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Jun 30, 2025, 8:36 PM EDT - 6 months ago

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Jun 11, 2025, 9:24 PM EDT - 7 months ago

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

May 14, 2025, 10:57 PM EDT - 8 months ago

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

May 5, 2025, 2:44 AM EDT - 8 months ago

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Apr 29, 2025, 8:53 PM EDT - 8 months ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Apr 28, 2025, 7:44 PM EDT - 8 months ago

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Apr 16, 2025, 9:20 PM EDT - 9 months ago

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Apr 3, 2025, 6:58 PM EDT - 9 months ago

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Apr 2, 2025, 7:15 PM EDT - 9 months ago

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

First Three Children to Commence Treatment With Ryoncil®

Mar 30, 2025, 7:39 PM EDT - 9 months ago

First Three Children to Commence Treatment With Ryoncil®

Ryoncil® is Now Available for Purchase in the United States

Mar 26, 2025, 8:19 PM EDT - 9 months ago

Ryoncil® is Now Available for Purchase in the United States

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mar 13, 2025, 7:42 PM EDT - 10 months ago

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mar 12, 2025, 7:30 AM EDT - 10 months ago

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Feb 28, 2025, 11:38 AM EST - 10 months ago

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Feb 26, 2025, 5:30 PM EST - 10 months ago

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Mesoblast Financial Results and Corporate Update Webcast

Feb 25, 2025, 6:13 PM EST - 10 months ago

Mesoblast Financial Results and Corporate Update Webcast

Dr. Gregory George MD PhD Joins Mesoblast Board

Feb 23, 2025, 6:33 PM EST - 10 months ago

Dr. Gregory George MD PhD Joins Mesoblast Board

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Feb 13, 2025, 6:37 PM EST - 11 months ago

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Ryoncil® Commercial Launch Update and Product Pipeline

Jan 30, 2025, 7:11 PM EST - 11 months ago

Ryoncil® Commercial Launch Update and Product Pipeline

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Jan 30, 2025, 6:20 PM EST - 11 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Dec 19, 2024, 6:38 AM EST - 1 year ago

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

Dec 18, 2024, 7:08 PM EST - 1 year ago

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Dec 18, 2024, 4:58 PM EST - 1 year ago

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Mesoblast to be Added to Nasdaq Biotechnology Index

Dec 18, 2024, 7:30 AM EST - 1 year ago

Mesoblast to be Added to Nasdaq Biotechnology Index

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Dec 12, 2024, 12:08 PM EST - 1 year ago

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

CAPR XBI

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Dec 4, 2024, 6:32 PM EST - 1 year ago

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Dec 2, 2024, 6:20 PM EST - 1 year ago

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Oct 30, 2024, 7:11 PM EDT - 1 year ago

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 30, 2024, 4:24 PM EDT - 1 year ago

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Sep 29, 2024, 8:55 PM EDT - 1 year ago

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Aug 28, 2024, 9:04 PM EDT - 1 year ago

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Aug 28, 2024, 7:27 PM EDT - 1 year ago

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

Jul 30, 2024, 9:13 PM EDT - 1 year ago

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

Doozio
Doozio Dec. 19 at 7:25 PM
$MESO much moar 🐒🍌🧠⏰♾️
0 · Reply
Portman62
Portman62 Dec. 16 at 3:02 PM
$MESO technicals show bullish for the next 9 months, I still see $22.00 before the end of the year … steady as she goes.
1 · Reply
Mani86
Mani86 Dec. 15 at 2:31 AM
$MESO https://www.marketindex.com.au/asx/msb/announcements/study-at-ash-concludes-remestemcell-superiority-in-sragvhd-3A683770
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 12 at 3:17 PM
$MESO Current Stock Price: $18.22 Contracts to trade: $20 MESO Dec 19 2025 Call Entry: $0.20 Exit: $0.27 ROI: 37% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Mani86
Mani86 Dec. 4 at 5:03 PM
$MESO After looking at the short squeeze in Capricor , shorters in mesoblast should get very worried cause one fine day the squeeze will come and they would have no choice but to buy back at significantly higher price☝️
0 · Reply
Portman62
Portman62 Dec. 3 at 3:09 PM
$MESO Let’s go MESO, I see nothing keeping you down, solid stock with a great history and future. 👏🏽👏🏽👏🏽
0 · Reply
zipperson
zipperson Nov. 26 at 6:07 PM
$MESO
0 · Reply
zipperson
zipperson Nov. 25 at 8:36 PM
$MESO
0 · Reply
zipperson
zipperson Nov. 25 at 4:50 PM
$MESO This is huge beating estimate by 50%.
0 · Reply
Portman62
Portman62 Nov. 25 at 2:34 PM
$MESO … and away we go, as it should.
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 1:38 PM
Jefferies has updated their rating for Mesoblast ( $MESO ) to Buy.
0 · Reply
hots
hots Nov. 25 at 12:38 PM
$MESO Great update on Q2 sales, lots of good catalysts over the next few months. I would watch for the JP Morgan event in January. Great opportunity to promote a deal
0 · Reply
AlertsAndNews
AlertsAndNews Nov. 25 at 3:37 AM
$MESO Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue "For the quarter ending December 31, 2025, management expects gross revenue of more than US$30.0 million from sales of Ryoncil® (remestemcel-L-rknd). This represents more than 37% increase on the US$21.9 million in gross revenue from Ryoncil® in the prior quarter ended September 30, 2025."
1 · Reply
SweepCastApp
SweepCastApp Nov. 18 at 2:13 AM
$MESO: Unusual Options Activity Alerted CALL flow observed 150x contracts at Strike price of $21 Exp on 04/17/2026 with Premium of $26K and showing BEARISH Sentiment
1 · Reply
zipperson
zipperson Nov. 17 at 6:24 PM
$MESO Pre Market Hour hits $16. It should be there by EOW. IMO
0 · Reply
zipperson
zipperson Nov. 17 at 3:01 PM
$MESO
1 · Reply
zipperson
zipperson Nov. 17 at 4:45 AM
$MESO James O’Brien’s appointment as a CFO is seen as a key move to bolster Mesoblast’s financial strategy amid its commercial expansion in the US. He is based in the New York City metropolitan area and is currently affiliated with Great Island Advisors, a financial advisory firm.
0 · Reply
zipperson
zipperson Nov. 16 at 7:23 AM
$MESO
0 · Reply
zipperson
zipperson Nov. 13 at 7:02 PM
$MESO Last dip to add…
0 · Reply
zipperson
zipperson Nov. 7 at 4:55 PM
$MESO nice setup for next year!
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 4 at 4:10 PM
Even up ~10% today, $SNDX continues to trade at much lower revenue multiples versus peers with similar profiles. The attachment speaks for itself This is not investment advice because we have no idea what will happen to SNDX's share price in the future. Analysts could lower their SNDX forecasts for all we know. Only $JAZZ trades at a lower FY26 multiple than SNDX. JAZZ is considerably more mature a company. Others with FY29 (Year 4) multiples within 50% of SNDX include $IMCR $MESO & $SLNO We'd genuinely like to understand any flaws using revenue multiple analytics.
1 · Reply
zipperson
zipperson Nov. 3 at 3:51 PM
$MESO cheap!
0 · Reply